Selective PDE10A Inhibitor Reduces Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative and psychiatric disorders often have side effects and are not efficacious for all patients, highlighting the need for alternative methods that can effectively target PDE10A enzyme to mimic D2 receptor antagonism with reduced extrapyramidal side effects.
Innovation Solution
A compound, 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1 H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine, is developed as a selective PDE10A enzyme inhibitor with improved solubility, metabolic stability, and bioavailability, which reverses PCP-induced hyperactivity by 99%, offering a potential alternative treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative and psychiatric disorders are used, then therapeutic effects are achieved, but side effects occur and efficacy is limited for all patients
Solution Approach 1:
The invention targets a specific enzyme subtype (PDE10A) within the broader phosphodiesterase family, segmenting the therapeutic approach to achieve selective inhibition. This specificity improves therapeutic efficacy while reducing off-target side effects by focusing on the particular enzyme responsible for regulating cAMP and cGMP in striatal neurons, rather than broadly inhibiting multiple PDE isoforms
Solution Approach 2:
The compound exhibits selective action localized to PDE10A enzyme, which is specifically expressed in striatal neurons. This local quality of selective inhibition allows the drug to modulate cyclic nucleotide levels precisely where needed (in the basal ganglia circuitry) without affecting other tissues or enzyme types, thereby improving reliability while minimizing harmful systemic effects
2Object-affected harmful factors
If PDE10A enzyme inhibition is achieved to mimic D2 receptor antagonism, then extrapyramidal side effects are reduced, but selective and effective compounds are needed
Solution Approach 1:
The compound acts as an intermediary substance that indirectly achieves antipsychotic effects by inhibiting PDE10A, which subsequently modulates cAMP and cGMP signaling pathways. This indirect mechanism mimics D2 receptor antagonism while avoiding direct dopamine receptor blockade, thereby reducing extrapyramidal side effects while maintaining therapeutic efficacy through downstream signaling modulation
3Ease of operation
If compound solubility and bioavailability are improved, then drug delivery is enhanced, but metabolic stability must be maintained
Solution Approach 1:
The compound structure incorporates specific chemical modifications (aromatic rings, heterocyclic moieties, methyl groups) that alter its physical and chemical parameters. These changes improve solubility and bioavailability by enhancing membrane permeability and dissolution properties, while simultaneously maintaining metabolic stability through strategic placement of metabolically stable functional groups that resist enzymatic degradation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits PDE10A enzyme activity with an IC50 value of about 2.2 nM and significantly reverses PCP-induced hyperactivity, demonstrating its potential as a more effective and side-effect-reduced treatment for neurodegenerative and psychiatric disorders.
Implementation Method 1
PDE10A is a dual-specificity phosphodiesterase that can convert both cAMP to AMP and cGMP to GMP
Implementation Method 2
PDEs are a class of intracellular enzymes that regulate levels of cAMP and cGMP via hydrolysis of the cyclic nucleotides into their respective nucleotide monophosphates
Data Source
AI summary
This invention provides the compound 5,8-Dimethyl-2-[2-(1 -methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof.